Molecular Brake Found That Keeps Lipid-Scrambling Protein TMEM63B Switched Off

Every living cell wraps itself in a plasma membrane whose two leaflets are not identical. Phosphatidylserine and phosphatidylethanolamine are actively kept on the inner, cytoplasmic face, while phosphatidylcholine and sphingolipids dominate the outer surface. This asymmetrical arrangement is far more than structural decoration: it underpins signaling, membrane curvature, blood coagulation, and the immune system’s ability to distinguish healthy cells from dying ones. When the barrier between leaflets collapses, the consequences can be dramatic, which is why cells guard the process of lipid scrambling with elaborate molecular locks. A new study from Institute of Science Tokyo, published in the Journal of Biological Chemistry, has now revealed one of those locks in fine molecular detail for TMEM63B, a mechanosensitive lipid scramblase whose uncontrolled activity has been implicated in severe neurological disease.

Lipid scramblases are proteins that shuttle phospholipids down their concentration gradient from one leaflet of the bilayer to the other, without consuming ATP. Unlike flippases, which actively maintain asymmetry, scramblases are built for rapid, passive equilibration once activated. Because such activity is potentially destructive, most scramblases are held in a tightly regulated off state and only open in response to specific triggers, such as a surge of calcium ions, caspase cleavage during apoptosis, or mechanical deformation of the membrane. TMEM63B belongs to a recently characterized family of mechanosensitive scramblases that respond to the physical state of the membrane itself, becoming active when properties such as bilayer thickness or curvature are altered. The central question addressed by the Tokyo team was deceptively simple: if membrane deformation activates TMEM63B, what keeps it silent when the membrane is at rest?

To answer it, a research team led by graduate student Megumi Nishimura, Lecturer Yugo Miyata, and Professor Katsumori Segawa of the Department of Medical Chemistry at Science Tokyo, working with Associate Professor Norimichi Nomura of Kyoto University and Professor Tomohiro Nishizawa of Yokohama City University, traced the regulatory machinery to the very end of the protein. Their study, made available online on June 4, 2026, and published in Volume 302, Issue 7 of the journal on July 1, 2026, demonstrates that an autoinhibitory segment within the intracellular C-terminal tail functions as a built-in molecular brake, locking the scramblase in its inactive conformation until genuine membrane cues release it. The work began, intriguingly, with an antibody rather than a mutant protein.

The researchers exploited YN9303-24, an antibody previously shown to push TMEM63B into its open conformation. Mapping where an antibody binds on a large membrane protein is a classic detective exercise, and the team used three complementary strategies: chimeric proteins that swapped regions between related molecules, progressive truncations that shaved the C-terminal tail shorter and shorter, and targeted deletions of individual amino acids. Together, these experiments localized the antibody-binding epitope to the intracellular C-terminal tail. Within that region, the antibody recognized a short three-residue AQV motif at positions 773 through 775. The finding was a useful clue, because an antibody that stabilizes the open state must bind somewhere that matters for conformational control, and the tail was now squarely in the frame.

The real regulatory hotspot, however, turned out to sit immediately next door. A neighboring LQD sequence spanning residues 776 to 778 proved essential for restraining the protein itself. When the researchers deleted these three amino acids, TMEM63B became constitutively active, scrambling lipids even in the absence of any mechanical stimulation of the membrane. Finer mutagenesis then isolated a single culprit: the leucine at position 776, known as Leu776. Substituting alanine for this one residue dramatically increased the exposure of phosphatidylserine on the cell surface, a striking result because PS is normally confined to the inner cytoplasmic leaflet of the plasma membrane in resting cells. Mutating the adjacent glutamine at position 777 or aspartate at position 778 produced no comparable effect, underscoring how exquisitely specific the brake is. Independent confirmation came from measuring the uptake of fluorescent phosphatidylcholine, which was markedly enhanced in the Leu776-mutant protein, consistent with a broadly opened lipid translocation pathway.

The C-terminal tail functions like a molecular brake, keeping TMEM63B inactive under resting conditions until changes in the membrane allow it to become activated, Segawa explains. The metaphor is apt at the structural level as well. In the open-state structure of the protein, the AQVLQD motif lies adjacent to two intracellular helices, IL2H2 and IL2H3, which form part of a beam-like intracellular domain of TMEM63B. Leu776 is positioned close to several hydrophobic residues within these helices, suggesting that the tail physically engages this intracellular scaffold through hydrophobic contacts. Such interactions would be well suited to stabilizing the closed, autoinhibited state: the tail effectively holds the gate shut by clasping the internal beam. When the hydrophobic contact is disrupted, whether by deletion, mutation, or a sufficiently strong mechanical cue, the restraint is released and the lipid pathway springs open.

This structural logic also offers a satisfying explanation for the antibody’s behavior. By binding the AQV motif immediately preceding the critical LQD sequence, YN9303-24 likely interferes with the very contacts that tether the tail to the intracellular domain, mimicking the effect of losing Leu776. In other words, the antibody and the point mutation converge on the same regulatory switch from opposite directions. The convergence strengthens the conclusion that this small patch of the C-terminal tail is not merely associated with regulation but is the mechanistic core of it, a compact decision point where mechanical information about membrane state is translated into the open or closed configuration of the translocation pathway.

Why should this molecular detail matter beyond the membrane biophysics community? The answer lies in the clinic. Earlier studies have linked disease-associated TMEM63B mutations to neurodevelopmental and neurodegenerative disorders, making the protein a gene of growing medical interest. Neurons are extraordinarily dependent on precise control of their membrane composition, both for electrical signaling and for the synaptic trafficking that underlies learning and memory. A scramblase that fires inappropriately would collapse phospholipid asymmetry, perturb countless lipid-dependent processes, and impose stress on cells that have little capacity to spare. Understanding how the C-terminal tail restrains TMEM63B gives a clearer picture of how inappropriate activation of this scramblase could disrupt membrane function and potentially contribute to neurological disorders, Segawa notes. In principle, disease mutations could act by weakening exactly the hydrophobic contacts that the Tokyo team has now identified, effectively removing the brake from within.

The study, whose authors declare no conflicts of interest, also carries a broader conceptual lesson about how mechanosensitive proteins are governed. Rather than relying solely on external triggers, TMEM63B carries an internal governor, a short tail segment tuned so finely that a single leucine determines whether the gate stays shut. This arrangement echoes autoinhibitory strategies seen in many signaling proteins, where a peripheral segment blocks the active site until a specific stimulus dislodges it. For scramblases, whose activity is intrinsically hazardous, such a built-in brake is an elegant evolutionary solution: the protein remains poised for rapid activation yet cannot leak into its dangerous open state by accident.

The researchers suggest that these findings provide a new framework for understanding TMEM63B regulation and could guide future studies into its role in disease pathogenesis and potential therapeutic strategies. If the Leu776-mediated brake proves to be weakened in patient-derived variants, small molecules that stabilize the tail-domain interaction might one day restore proper gating. Conversely, controlled activation of scramblase activity remains attractive in contexts where exposing phosphatidylserine is therapeutically useful. For now, the work stands as a crisp demonstration that one hydrophobic residue at the tip of a tail can hold an entire membrane-remodeling machine in check, a reminder that in molecular biology the most consequential switches are often the smallest.

Subject of Research: Autoinhibition of the mechanosensitive lipid scramblase TMEM63B by its C-terminal tail

Article Title: Demonstrating the molecular mechanism that regulates TMEM63B lipid scrambling

Article References: Demonstrating the molecular mechanism that regulates TMEM63B lipid scrambling. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: TMEM63B, lipid scramblase, C-terminal tail, Leu776, phosphatidylserine, membrane asymmetry, mechanosensitive protein, autoinhibition, plasma membrane, neurodegenerative disease, Journal of Biological Chemistry, conformational regulation